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INTRODUCTION
Radiofrequency (RF) ablation has been proved to be an 
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Objective: Arsenic trioxide (As2O3) can be used as a possible pharmaceutical alternative that augments radiofrequency (RF) 
ablation by reducing tumor blood flow. The aim of this study was to assess the effect of intraarterial and intravenous 
administration of As2O3 on RF-induced ablation in an experimentally induced liver tumor. 
Materials and Methods: VX2 carcinoma was grown in the livers of 30 rabbits. As2O3 (1 mg/kg) was administered through 
the hepatic artery (n = 10, group A) or ear vein (n = 10, group B), 30 minutes before RF ablation (125 mA ± 35; 90 ± 5°C). 
As a control group, 10 rabbits were treated with RF ablation alone (group C). RF was intentionally applied to the peripheral 
margin of the tumor so that ablation can cover the tumor and adjacent hepatic parenchyma. Ablation areas of the tumor 
and adjacent parenchymal changes among three groups were compared by the Kruskal-Wallis and Mann-Whitney U test.
Results: The overall ablation areas were 156 ± 28.9 mm
2 (group A), 119 ± 31.7 (group B), and 92 ± 17.4 (group C, p < 
0.04). The ablation area of the tumor was significantly larger in group A (73 ± 19.7 mm
2) than both group B (50 ± 19.4, p 
= 0.02) and group C (28 ± 2.2, p < 0.01). The ratios of the tumoral ablation area to the overall ablation area were larger in 
group A (47 ± 10.5%) than that of the other groups (42 ± 7.3% in group B and 32 ± 5.6% in group C) (p < 0.03).
Conclusion: Radiofrequency-induced ablation area can be increased with intraarterial or intravenous administration of 
As2O3. The intraarterial administration of As2O3 seems to be helpful for the selective ablation of the tumor.
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effective treatment in unresectable malignant liver tumors 
(1-3). However, it has an inherent limitation in the volume 
of tumors which can be effectively ablated. Consequently, 
clinical data demonstrated excellent local tumor control 
(80-90%) in tumors < 3 cm in the diameter, but much less 
satisfactory results (50-75%) in larger tumors (1-3). This 
limitation is mainly caused by perfusion-mediated tissue 
cooling, heat sink effect (4). Therefore, several adjunctive 
techniques have been developed to reduce regional and 
intratumoral blood flow, and increase the ablation time. 
These include hepatic arterial occlusion by balloon catheter 
(5), transcatheter hepatic arterial embolization (6), bipolar 
array technique (7), saline injection (8), and pharmacologic 
modulation (9).
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Contrary to their infamous carcinogenic properties as an 
environmental pollutant, arsenic compounds have been 
used for medical purposes for several thousand years (10). 
Recently, arsenic trioxide (As2O3) was found to be highly 
effective for the treatment of acute promyelocytic leukemia 
(APL) (11, 12). Thereafter, it has been widely tested in 
treating not only-APL leukemia but also a variety of solid 
tumors including hepatocellular carcinoma (HCC) (11, 13, 
14). The mechanism of As2O3 activity against solid tumors 
has not been completely understood. However, previous 
studies discovered As2O3 induces tumor vascular shutdown, 
and subsequently potentiates hyperthermal therapy (15, 
16). Hines-Peralta et al. (17) have shown that systematic 
administration of As2O3 enables larger zones of RF ablation 
in various experimentally induced tumor models. However, 
in their study, optimal results were achieved with a 
relatively high dose of this toxic drug and the synergistic 
effect has a narrow temporary window (18). Generally the 
hepatic artery is a better route of drug administration than 
systemic veins for the treatment of liver tumors (19, 20). 
Thus, we hypothesized that hepatic arterial administration 
of As2O3 may induce larger zones of RF ablation than 
intravenous administration. The purpose of this study is to 
assess the effects of hepatic arterial administration of As2O3 
on RF-induced ablation and compare them with those of 
systemic venous administration in a liver tumor model.
MATERIALS AND METHODS
Liver Tumor Model and Experimental Groups
All the experiments associated with this study were 
approved by our Institutional Animal Care And Use 
Committee. All rabbits were maintained according to the 
Guide for the Care and Use of Laboratory Animals (21). 
Thirty adult New Zealand white rabbits weighing 2.5-3.0 kg 
were used. The VX2 carcinoma strain had been maintained 
by means of successive transplantation into the hindlimb of 
the carrier rabbit. Anesthesia was induced with intravenous 
ketamine hydrochloride (50 mg per kilogram of body 
weight; Ketamine, Yuhan, Korea) and 2% xylazine (0.1 mL/
kg; Rompun, Bayer, Germany). After a midline abdominal 
incision, 0.1 mL of minced VX2 carcinoma was implanted 
into the subcapsular parenchyma of the left medial lobe of 
the liver. Fourteen days after tumor implantation, when the 
tumors were anticipated to be 10-20 mm in diameter, the 
rabbits were used for the experiments.
One day before RF ablation, contrast-enhanced liver CT 
(Sensation 16; Siemens, Erlangen, Germany) was performed 
to confirm the presence and size of the liver tumors. On the 
basis of the longest diameter of the tumor, the rabbits were 
divided into three groups (groups A-C). The spontaneous 
necrosis of a VX2 liver tumor can be influenced by tumor 
size, which subsequently affects the results of our study. 
Therefore, rabbits with similar sized tumors were assigned 
to each group. The longest diameter of tumors ranged from 
13.2 to 20.5 mm (18 ± 2.0 mm; median 17.4 mm mean ± 
standard deviation [SD]) in group A, 13.8 to 21.3 mm (17 
± 2.0 mm, 16.2 mm) in group B, and 11.7 to 20.0 mm (17 
± 3.1 mm, 17.6 mm) in group C. Tumor volumes were not 
statistically different among the three groups (p = 0.687, 
Kruskal-Wallace test).
Arsenic Trioxide Administration and Radiofrequency 
Ablation
A solution of As2O3 (Sigma, St. Louis, MO, USA) was 
prepared by magnetic stirring for one day at room 
temperature in a glass bottle and then placed the bottle 
into boiling water for one hour. After the solution became 
crystal clear, it was sterilized using a 0.2 M bottle-
top filter and stored in the dark at 4°C. Just before the 
administration, the stock solution was then diluted with 
phosphate-buffered saline to a concentration of 1 mg/mL.
In group A, the As2O3 solution was administered through 
the hepatic artery. Under general anesthesia, an incision 
was made to access the right femoral artery. The celiac 
angiogram was obtained to identify the hepatic arterial 
anatomy and the feeder artery of the tumor using a 
3-Fr microcatheter (Cook, Bloomington, IN, USA). After 
positioning the catheter within the proper hepatic artery, 1 
mL/kg of the As2O3 solution (1 mg/kg) was slowly injected 
at a rate of 180 mL/hr using an infusion pump. The catheter 
was then removed and the femoral artery was ligated. In 
group B, the As2O3 solution was administered into the 
auricular vein. The amount of As2O3 solution and infusion 
rate were the same in group B. In group C, the same volume 
of phosphate-buffered saline was infused into the auricular 
vein.
One hour after completing the As2O3 solution or 
phosphate-buffered saline injection, RF ablation of the 
liver tumor was performed. Under general anesthesia, a 
midline incision was made to expose the liver. A 500-kHz 
RF generator (Valley-Lab, Boulder, CO, USA) was used to 
apply conventional monopolar RF energy. An internally 
cooled, 17-gauge electrode (Radionics) with a 1-cm active 197
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tip was placed in at peripheral margin of the tumor so 
that the tumor tissue and normal parenchyma were ablated 
simultaneously (Fig. 1A). RF energy was applied for five 
minutes with the generator output titrated to maintain 
a designated tip temperature: a mean temperature of 90 
± 2°C. RF ablation was performed in random order by an 
investigator who was unaware of the treatment groups.
Histopathologic Examinations
Euthanasia of animals was performed with pentobarbital 
after RF ablation immediately, and the livers were excised. 
Each tumor was sectioned at 2-3 mm intervals in a cross-
sectional fashion, perpendicular to the line of the RF 
electrode tract. The representative slices were soaked in 2% 
2,3,5-triphenyltetrazolium chloride (TTC) (Fisher Scientific, 
Fairlawn, NJ, USA) for 30 minutes. With this method, viable 
tissue with intact mitochondrial enzyme activity stains 
red, while ablated tissue does not turn red. The absence of 
mitochondrial enzyme activity has been shown to accurately 
reveal irreversible cellular injury by percutaneous tumor 
ablation. The ablation areas were measured with use of 
software (Image-Pro Plus, Media Cybernetics, Silver Spring, 
MD, USA) (Fig. 1B). Overall ablation area included tumor 
ablation area and non-tumorous parenchymal ablation 
area (Fig. 1C). The ratio of tumoral ablation area to overall 
ablation area was calculated to verify whether the effect 
of As2O3 on RF ablation area has selectivity for liver tumor. 
The ablation areas of the three groups were compared with 
Kruskal-Wallis and Mann-Whitney U test. The p value < 0.05 
was considered significant. Microscopic examination was 
also performed in all specimens with Hematoxylin and Eosin 
staining. All the histologic evaluations were performed by a 
pathologist unaware of the experimental groups.
RESULTS
Gross examination showed the ablation lesion in each 
specimen as oval-shaped paled area of ablation necrosis 
including the VX2 tumor and adjacent normal liver 
parenchyma, the central tissue loss areas around the needle 
track, and peripheral thin dark-brown hemorrhagic rim (Fig. 2).
The ablation areas on TTC stained specimen were graphed 
in Figure 3A. The overall ablation areas were measured as 
111.7-208.7 mm
2 (mean, 156 ± 28.9 mm
2; median, 151.0 
mm
2) in group A, 61.5-169.2 mm
2 (mean, 119 ± 31.7 
mm
2; 115.2 mm
2) in group B, 63.4-127.5 mm
2 (mean, 
92 ± 17.4 mm
2; 90.4 mm
2) in group C. The difference in 
overall ablation areas of the three groups were statistically 
significant (p < 0.001). Overall ablation area of group A was 
larger than those of group B (p = 0.019) and group C (p < 
0.001). The difference between group B and group C was 
also statistically significant (p = 0.029) (Fig. 3A).
Tumoral ablation areas were measured as 35.2-104.4 mm
2 
(mean, 73 ± 19.7 mm
2; 70.9 mm
2) in group A, 24.1-93.6 
mm
2 (mean, 50 ± 19.4 mm
2, 48.2 mm
2) in group B, 25.8-
30.8 mm
2 (mean, 28 ± 2.2 mm
2, 28.9 mm
2) in group C. The 
tumoral ablation area of group A was significantly larger 
than those of group B (p = 0.019) and group C (p < 0.001). 
The difference between group B and C was not statistically 
significant (p = 0.247) (Fig. 3B).
The ratios of tumoral ablation area to overall ablation 
area were calculated as 32-60% (mean, 47 ± 10.5%; 
VX2 tumor RF ablation VX2 tumor RF ablation VX2 tumor RF ablation
A B
A B C
Fig. 1. Experimental concept of intentional marginal ablaion.
A. Radiofrequency electrode (small black dot) was placed at peripheral margin of tumor to simultaneously induce tumor and hepatic parenchymal 
ablation. B. Overall ablation area. Illustration showing overall ablation area (white circle) includes tumor ablation area and hepatic parenchymal 
area. C. Selectivity of As2O3 effect. Illustration showing coagulated tumor area (A) and coagulated hepatic parenchymal area (B). Each area was 
measured to verify whether selective antivascular property of As2O3 on liver tumor has influence on radiofrequency ablation. Radios of coagulated 
tumor area versus coagulated hepatic parenchymal area were calculated.198
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median, 45%) in group A, 31-55% (mean, 42 ± 7.3%; 39%) 
in group B, 24-41% (mean, 32 ± 5.6%; 30%) in group C. 
The difference among the ratios of the three groups were 
statistically significant (p = 0.002). The ratios of group A 
and B were significantly larger than that of group C (p = 
0.001 and 0.003, respectively). However, the difference 
between group A and B was not statistically significant (p = 
0.218) (Fig. 3C).
DISCUSSION
To overcome the heat sink effect, there have been various 
trials to extend the area of the ablation including the 
hepatic artery embolization, interstitial saline injection, and 
pharmacologic modulation (5-9). Pharmacologic approaches 
aim to reduce hepatic arterial flow to the tumor and to 
prevent heat dissipation, and subsequently augment the 
area of ablation necrosis induced by RF ablation. Therefore 
the ideal agent for this approach should be able to reduce 
blood flow of the target tumor selectively and preserve 
blood flow of non-tumoral hepatic parenchyma. In recent 
investigations, several drugs including halothane and As2O3 
reduced tumoral blood flow selectively and expanded the RF 
ablation area in the VX2 liver and renal tumor models (9).
Although the action mechanism of As2O3 is not fully 
understood, previous studies showed that single or 
multiple doses of 8-10 mg/kg of As2O3 cause marked tumor 
vascular shutdowns and increased the anti-tumor effect 
of hyperthermic and radiation therapy in experimental 
solid tumors (15, 22, 23). Therefore, As2O3 is a promising 
pharmacologic modulator to overcome the limitation 
of hyperthermic ablation therapy (9, 17, 18). A recent 
study by Hines-Peralta et al. (17) found intravenous As2O3 
administration induced larger ablation necrosis in a liver 
tumor model. This study is in accordance with their results 
demonstrating a larger ablation area in the intravenous 
As2O3 group compared with the control group (118.7 mm
2 
versus 63.4 mm
2) (9, 14, 15, 17). Furthermore, we found 
that significant augmentation of the RF ablation area could 
be achieved by intraarterial As2O3 administration as well as 
by intravenous administration.
In our study, the intraarterial group showed a larger 
ablation area than those of the intravenous group (155.8 
mm
2 versus 118.7 mm
2). This result might is not unexpected 
considering that trans-arterial treatment is generally 
accepted as a more effective approach than systemic 
treatments in liver tumors (24). In a biodistribution 
study employing intravenous administration of As2O3, the 
tissue concentration of monomethylarsinic acid, a major 
metabolite of As2O3, was highest in the lung and kidney, 
suggesting most of systemically administered As2O3 is 
metabolized in organs other than the liver (25). Thus, 
we think that hepatic arterial administration of As2O3 is a 
more favorable strategy than the intravenous approach to 
increase the local concentration and avoid the toxicity in 
treatment of liver tumors.
Arsenic trioxide has a very narrow therapeutic window. 
A dose of As2O3 more than 5 mg/kg shows signs of liver 
A B C
Fig. 2. Triphenyltetrazolium chloride stained specimens. With triphenyltetrazolium chloride staining, viable tissue with intact 
mitochondrial enzyme activity stains red, while ablated tissue remains white. Arrow indicating VX2 carcinoma and arrowheads point to ablated 
area. Ablated area of specimen from group A is larger than that from group B and C.
A. Specimen from group A administered through hepatic artery. B. Specimen from group B administered through auricular vein. C. Specimen from 
group C, control group, administered phosphate-buffered saline through auricular vein.199
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and kidney toxicity when administered intraperitoneally or 
intravenously. Conversely, a low dose of As2O3 less than 1 
mg/kg shows an opposite effect including the promotion 
of tumor growth, up-regulated tumor angiogenesis and 
no effect on tumor cell apoptosis (26, 27). Thus, it is 
important to determine the dose of As2O3 and the timing 
of the RF ablation after As2O3 administration. Based on a 
previous study employing intravenous administration of 
As2O3 in rabbit model (17), we adopted 1 mg/kg of As2O3 
and ablated the tumor one hour after As2O3 administration. 
We didn’t confirm the optimal dose and temporal window 
in the intraarterial administration because this study did 
not include a dose escalation study component. However, 
despite an optimal dose and timing of intravenous 
As2O3 administration larger ablation was achieved in the 
intraarterial group. Therefore, we believe that a bigger 
difference between intravenous and intraarterial groups 
would be achieved if the optimal dose and timing for 
intraarterial administration was used.
During the RF ablation procedure, we intentionally 
located the RF electrode at the margin of the VX2 tumor 
to simultaneously induce ablation necrosis in both tumor 
and normal liver parenchyma (Fig. 1). This technique was 
made to determine whether As2O3 has a selective effect on 
tumor tissue. The ratio of the tumor ablation area to overall 
ablation area was used as an index of tumor selectivity. 
The ratios of the intraarterial and intravenous group were 
significantly higher than that of the control group. These 
results support the previous report which showed a greater 
decrease of tumoral blood flow than normal parenchymal 
flow after As2O3 administration (17). Therefore, As2O3 seems 
to have a selective anti-vascular effect on tumor tissue. 
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Fig. 3. Result of tumor ablation in each experimental group.
A. Graph demonstrating overall ablation area in each group confirmed by triphenyltetrazolium chloride staining. Ablation was performed one hour 
after administration of arsenic trioxide in each group. Overall ablation area of group A was larger than that of group B (p < 0.01) and C (p < 0.001). 
Difference between group B and C was also statistically significant (p < 0.04). B. Graph demonstrating coagulated tumor area in each group. 
Ablation tumor area in group A was significantly larger than that of group B (p = 0.02) and C (p < 0.01). Difference between group B and C was 
not statistically significant. C. Graph demonstrating ratio tumor ablation of overall ablation area in each group, confirmed by triphenyltetrazolium 
chloride staining.200
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This result suggests pharmacologic modulation using As2O3 
as a favorable technique to augment RF ablation compared 
to other strategies such as hepatic artery embolization and 
interstitial saline injection. From a clinical aspect, combined 
treatment with As2O3 and other chemoembolic materials 
should be investigated for the radiofrequency ablation 
procedure because trans-arterial chemoembolization with 
radiofrequency ablation is already used in practice.
This study has important limitations. First, the optimal 
dose of As2O3 and temporal window for RF ablation was not 
evaluated. Further studies employing various doses and time 
intervals should be performed to find the optimal setting 
for intraarterial As2O3 administration. Second, we evaluated 
tumoral selectivity of As2O3 effect comparing tumoral and 
non-tumoral ablation areas. However, this method can be 
influenced by many factors such as exact position of the 
electrode and presence of adjacent large vessels. We think 
this limitation can be overcome by employing methods to 
measure tumoral blood flow directly such as laser Doppler 
flowmetry. Third, we did not perform tumor ablation and 
normal liver parenchymal ablation with an independent 
ablation method. Because the two ablations were impossible 
to separate for small rabbit liver, we intentionally targeted 
the tumor margin to perform the simultaneous ablation and 
to reduce the number of experimental animals. Fourth, we 
only have analyzed the ablation zone by a two dimensional 
pathologic method, but the three-dimensional analysis of 
the ablation zone would be necessary to evaluate the heat 
sink effect.
In conclusion, As2O3 administration selectively augments 
RF-induced ablation in a VX2 liver tumor. Hepatic arterial 
administration is a favorable approach to induce larger 
ablation than intravenous administration. Further studies 
are recommended to verify the optimal dose and temporal 
window for intraarterial administration of As2O3.
REFERENCES
1. Lencioni R, Crocetti L. Image-guided thermal ablation 
of hepatocellular carcinoma. Crit Rev Oncol Hematol 
2008;66:200-207
2. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, 
et al. Sustained complete response and complications rates 
after radiofrequency ablation of very early hepatocellular 
carcinoma in cirrhosis: is resection still the treatment of 
choice? Hepatology 2008;47:82-89
3. Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency 
thermal ablation of hepatic metastases. Eur J Ultrasound 
2001;13:149-158
4. Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, 
Athanasoulis CA, et al. Percutaneous radiofrequency tissue 
ablation: does perfusion-mediated tissue cooling limit 
coagulation necrosis? J Vasc Interv Radiol 1998;9:101-111
5. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchiano A, 
Fornari F, et al. Percutaneous radio-frequency thermal ablation 
of nonresectable hepatocellular carcinoma after occlusion of 
tumor blood supply. Radiology 2000;217:119-126
6. Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A. 
Percutaneous radiofrequency thermal ablation combined with 
transcatheter arterial embolization in the treatment of large 
hepatocellular carcinoma. Ultraschall Med 1999;20:47-53
7. McGahan JP, Gu WZ, Brock JM, Tesluk H, Jones CD. Hepatic 
ablation using bipolar radiofrequency electrocautery. Acad 
Radiol 1996;3:418-422
8. Livraghi T, Goldberg SN, Monti F, Bizzini A, Lazzaroni S, 
Meloni F, et al. Saline-enhanced radio-frequency tissue 
ablation in the treatment of liver metastases. Radiology 
1997;202:205-210
9. Horkan C, Ahmed M, Liu Z, Gazelle GS, Solazzo SA, Kruskal 
JB, et al. Radiofrequency ablation: effect of pharmacologic 
modulation of hepatic and renal blood flow on coagulation 
diameter in a VX2 tumor model. J Vasc Interv Radiol 
2004;15:269-274
10. Waxman S, Anderson KC. History of the development of 
arsenic derivatives in cancer therapy. Oncologist 2001;6 Suppl 
2:3-10
11. Murgo AJ. Clinical trials of arsenic trioxide in hematologic 
and solid tumors: overview of the National Cancer Institute 
Cooperative Research and Development Studies. Oncologist 
2001;6 Suppl 2:22-28
12. Tamm I, Paternostro G, Zapata JM. Treatment of acute 
promyelocytic leukemia with arsenic trioxide. N Engl J Med 
1999;340:1043; author reply 1044-1045
13. Tan B, Huang JF, Wei Q, Zhang H, Ni RZ. Anti-hepatoma 
effect of arsenic trioxide on experimental liver cancer 
induced by 2-acetamidofluorene in rats. World J Gastroenterol 
2005;11:5938-5943
14. Xu HY, Yang YL, Liu SM, Bi L, Chen SX. Effect of arsenic 
trioxide on human hepatocarcinoma in nude mice. World J 
Gastroenterol 2004;10:3677-3679
15. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. 
Arsenic trioxide induces selective tumour vascular damage via 
oxidative stress and increases thermosensitivity of tumours. 
Int J Hyperthermia 2003;19:575-589
16. Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, 
Hasegawa T. Study of arsenic trioxide-induced vascular 
shutdown and enhancement with radiation in solid tumor. 
Radiat Med 2004;22:205-211
17. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu 
ZJ, Goldberg SN. Improved tumor destruction with arsenic 
trioxide and radiofrequency ablation in three animal models. 
Radiology 2006;240:82-89
18. Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, 201
Intraarterial vs. Intravenous Administration of As2O3 on RFA of VX2 Liver Tumor
Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org
Signoretti S, et al. Combination of radiofrequency ablation 
with antiangiogenic therapy for tumor ablation efficacy: study 
in mice. Radiology 2007;244:464-470
19. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, 
Hicks M, et al. Dr. Gary J. Becker Young Investigator Award: 
intraarterial adenovirus for metastatic gastrointestinal cancer: 
activity, radiographic response, and survival. J Vasc Interv 
Radiol 2003;14:279-290
20. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner 
A, Ignoffo RJ, et al. A randomized trial of continuous 
intravenous versus hepatic intraarterial floxuridine in patients 
with colorectal cancer metastatic to the liver: the Northern 
California Oncology Group trial. J Clin Oncol 1989;7:1646-
1654
21. Institute of Laboratory Animal Resources Committee on 
Revision of the Guide for Laboratory Animals Facilities and 
Care of the Institute of Laboratory Animal Resources National 
Research Council, 3rd revised ed, 1968. Guide for laboratory 
animal facilities and care. Washington, DC: U.S. Public Health 
Service Publication No. 1024, 19681968
22. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic 
trioxide causes selective necrosis in solid murine tumors by 
vascular shutdown. Cancer Res 1999;59:6033-6037
23. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP 
Jr, et al. Arsenic trioxide induces dose- and time-dependent 
apoptosis of endothelium and may exert an antileukemic 
effect via inhibition of angiogenesis. Blood 2000;96:1525-
1530
24. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 
2001;2:418-428
25. Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL. Tissue 
distribution of arsenic species in rabbits after single and 
multiple parenteral administration of arsenic trioxide: tissue 
accumulation and the reversibility after washout are tissue-
selective. Cancer Chemother Pharmacol 2005;55:170-178
26. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, et 
al. Opposing effects of arsenic trioxide on hepatocellular 
carcinomas in mice. Cancer Sci 2006;97:675-681
27. Wang SS, Zhang T, Wang XL, Hong L, Qi QH. Effect of arsenic 
trioxide on rat hepatocellular carcinoma and its renal 
cytotoxity. World J Gastroenterol 2003;9:930-935